Proteologix

Proteologix is a biopharmaceutical company focusing on autoimmune diseases, with a core product portfolio including PX128 and PX130. PX128 is a bispecific antibody targeting IL-13 and TSLP, which is about to enter Phase I clinical trials for moderate to severe atopic dermatitis (AD) and moderate to severe asthma. PX130 is a bispecific antibody targeting IL-13 and IL-22, currently in the preclinical development stage for moderate to severe AD.